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Controversy surrounds the introduction of sny new drug in 
clinical medicine. Any novel therapeutic approach can be 
expected to be the focus of a vigumus debate concerning its 
efficacy, advantages and disadvantages when compared with 
those of already available drugs and devices, and the selec- 
tion of patients most likely to benefit from treatment. In most 
cases, after several years of use, the appropriate role of the 
drug is defined and the controversy that followed its initial 
introduction eventually subsides. Given this expected se- 
quent% of events, it is remarkable how long the controversy 
concerning the utility and safety of digbalis in the treatment 
of congestive heart failure has persisted. This drug has been 
the subject of the longest running debate in the history of 
cardiovascular medicine. 
Is dtt au effeetjve drun ht the treatmea, of heart 
failure??he classic treatise on-digitalis by William Wither- 
ing (I), “An Account of the Foxglove,” was published in 
1785. Since that time, controversy concerning the eihcacy OS 
digitalis in patients with congestive heart failure has never 
waned. Swn after the publication of Withering’s report. a 
debate ensued wgardiag the mechanism of action of digkalis 
and the selection of patients most likely to respond to the 
drug. Sir James Mackenzie (2) suggested in 1920 that the 
benefits of digitalis were seen only in patients who had atrial 
arrhythmias: ‘If we scrutinize the published records of cases 
that have benefited by the drug we find that the great 
maioritv of these results occur in one condition. auricukn 
fibballa~on or its allied condition, auricuku flutter”. A 
different v$wpoint was expressed in 1922 by Henry Cbris- 
tian (3): “The views of Sir James Mackenzie have been 
concurred in by numerous observers with the result that 
there is a growing feeling that unless the pulse is absolutely 
irregular and rapid. little is to be gained from digitalis 
therapy. My own view with regard to digitalis is that digitalis 
as a rule has a striking effect on those changes in the patient 
which are brought about by cardiac insufficiency and this 
elect appears irrespective of whether or nut the pulse is 
irregular.” During the last 60 to 70 years. there has been 
general agreement hat digitalis is valuable in patients with 
heart tailure accompanied by atrial fibrillation and a rapid 
ventricular responre. but there remains tu this day a con- 
tinuisg debate about the efficacy of digitalis in patients with 
heart failure who have normal sinus rhythm. 
Physicians who treat large numbers of patients with 
congestive heart failure have undoubtedly seen some pa- 
tients with sinus rhvtbm who have resnunded favorablv to 
digita’is therapy. J&spite this corruon experience, b is 
remarkable how few placcbo.contmlled oubtc-blind studies 
are wailable that can address this question with confidence. 
In the United Kinadorn. the use of diaitatis has diminished. 
in large part as a result of several studies (4-8) that suggested 
that digitalis was nut clinically beneficial in patients with 
sinus rhythm. In these studies, the withdrawal of maintc- 
name diiitalis therapy front patients with chmnic heart 
failure produced no deleterious effects. but the data could be 
readily criticized on several accounts. Many of the patients 
in these trials probably did not have congestive heart failure. 
Othen may have bad ~yrnptoms of heart failure as a result of 
diastolic (rather than systolic) dysfunction and their condi- 
tion would not have been expected to improve after treat- 
ment with a positive inotropic agent. Still others bad right 
heart failure secoadary to chronic pulmonary disease-a 
condition that responds poorly to digitalis. On the other 
bnnd, few studies (‘&IS) have actually shown any benefit 
from digitalis therapy, either bemodynamicrdly or clinically, 
even in patients most likely to impmve during treatment aitb 
the drug. In my own view. digitalis exerts modest positive 
inotropk effects that can benefit sonte patients with heart 
failure who are in rem&r sinus rhythm. These favorable 
effects are primarily &en in patients whose heart failure 
syndrome is accompanied by systolic dysfunction, left ven- 
triculor dilation and a third heart sound, and do not occur in 
patients with symptoms of heart failure due to diastolk 
dysfunction. 
Dues diaitatb edvemely a&et mortality in heart failore? In 
addition toconcerns abuut the long-tertn efficacy ofdigitulis, 
there are questions and controversy surrounding a possible 
adverse effect of digitalis on the mortality of patients with 
chronic cardiovascular disorders. Patients recovering from 
an acute mywardial infarction who are treated with digitalis 
uppar to have a higher mortality rate than do patients who 
do not receive the drug, even when mortality rates are 
corrected fur the greater prevalence of congestive heart 
failure in digitalis-treated patients (16.173. These observa- 
tions have reinforced previous fears about the risks of 
worsening ventricular arrhythmias with digitalis. especially 
when the drug is administered in toxic doses or in the 
presence ofmyocardial ischemia or electrolyte disturbances. 
Although the studies of Moss (16) and Bigger (17) and their 
colleagues have suggested that digitalis may have an adverse 
effec: an mortality, these retrospective analyses may not 
have adequately xcounted for the possibility that digitalis- 
treated patients had a higher number of mmrassred cardio- 
vascular isk factors (severity ofleft ventricular dysfunction 
and coronary artery disease. for example) that may have 
contributed to their higher mortality rate independent of an 
el%ct of digitalis. Other studies (18.19) have not been able to 
confirm an adverse effect of digitalis in patients recovering 
from an acute myocardial infarction. 
Concerns about an adverse effect of digitalis on mortality 
have been heightened by observations that other positive 
inotmpic agents (the phosphodierterase inhibitors. for ex- 
ample) may exert a similar unfavorable ffect on the survival 
ofpatients with chronic heart failure. Although drugs such as 
amrinone and milrinone produce dramatic short-term hemo- 
dynamic and clinical benefits, long-term treatment with these 
dtuss may be accompanied by specific deleterious effects 
(20). These drugs may enhance myocardial oxygen consump- 
tion, thereby provoking myocardial ischemia nd accelerating 
the rate of wxression of the underlvinc hean disease. These 
agents mai &awte ventricular &hythmias, thereby in. 
creasing the risk of sudden death. Prolonged inotropic stim- 
ulation may produce direct toxic elfects similar to those that 
have been reported for the catecholamines (211. Regardless of 
the specific mechanism. such observations have raised con- 
cerns that o/l positive inotmpic agents (including digitalis) 
may adversely affect survival. This conclusion may not be 
valid, however, becausethe mechanismoftheinotropicelfect 
of digitalis differs substantially from that of the catechola- 
mines and the phophodiesterase inhibitors. Furthermore, the 
more modest cardiostimulatory action ofdigitalis (when com- 
pared with that of other inotrovic drucsl mw limit any 
;nfavorable effect of the glycasid& on lo&ter~mortality.~ 
Although it remains unknown whether digitalis exerts a 
deleterious etTect on survival in chronic heart failure. no 
study has ever suggested that digitalis can prolor~g life in 
these severely ill patients. 
Should vasodilator drugs he considered firs1 line agents in 
heart failure? Consequently, although digitalis may be ben- 
eficial in :he trealment of chronic heart failure. the lack of 
evidence that the drug can prolong life raises the possibility 
that other agents (particularly vasodilator drugs) should he 
used beJore digitalis is administered in the management of 
patients with failure. Vasodilator drugs have rapidly become 
an established approach to tbc treatment of chronic heart 
failure, hut not all vasodilator agents can he considered 
potential candidates for first line agents in this disorder. 
Although aneriolar vasodilators uch as hydralazine (22) and 
minoxidil (23) can increase cardiac output and reduce sys- 
temic vascular esistance. both agents have failed to improve 
exercise tolerance in placebo-controlled trials and they may 
increase the frequency of adverse cardiovascular events 
(24.25). In contrast. drugs that primarily lower ventricular 
tilling pressures (nitrates and converting enzyme inhibitors. 
for example) can enhance exercise capacity and may favor- 
ably affect survival (26.27). In the V&era& Admin&mtion 
Vasodilator Heart Failure Trial (V-HeFD(28). acombination 
of isosorbide dinitrate and hydralazine reduced mortality in 
treated patients compared with those receiving placebo. No 
beneficial effect on survival was seen in pramsin-treated 
patients. possibly because of the develop& of tachyphy- 
laxis to this drug (291. In a lame placebo-contmlled trial with 
enalapril(30). c&erting enz~rn~ inhibition prolonged life in 
patients with severe symptoms; available data (31) are sug- 
gestive of a similar beneficial effect with captopril. These 
observations raise Ihe possibility that drugs that prolong life 
should be considered before digitalis is utilized in the man- 
agement of patients with chronic congalive heart failure. 
This qnrsfim does not rule ON the desirubiliry of using 
di&lis in combination with wsodilaum in pnlienls with 
conpmiw hrorl Jiiibm. These two therapeutic approaches 
act bv different mechanisms that are theoreticallv svnernis- 
tic. Both digitalis and vasodilators produce addi& he&- 
dynamic benefits (32). which may be translated into additive 
effects on exercise capacity. Finally, all of the patients who 
were enrolled into trials that showed a favorable effect of 
vasodilators an survival have been treated with digitalis. 
Hence. combination therapy of digitalis and vasodilators 
may prove to be the optimal therapeutic approach in many 
patients with heart failure. 
Thedebale. It is generally accepted that diuretics should 
he considered to be first line agents in the treatment of 
congestive heart failure. Despite concerns about the stimu- 
latory action of diuretics on neurohormonal systems and 
theirpredilection toproduceelectrolyte deficits(33). diuretic 
therapy is predictably followed by a rapid and dramatic 
amclionlion in symptoms. Nondiuretic therapeutic ap- 
pmaches usually fail to address the salt retention that is such 
; dominant fe&re in mat patients with chronic heart 
failure. Few patients with chronic heart failure can he 
withdrawn from diuretics. even though their condition may 
improve substantially a& treatment with digitalis or vase- 
dil&rs. If we then~sssume that most patients with heart 
failure will be treated with diuretics. which agent should be 
prescribed after diuretics in patients with persistent symp- 
toms? This question is addressed in the following commen- 
taries by Thomas Smith and Bertrdm Pitt. 
II. Protagonist’s Viewpoint 
THOMAS W. SMITH. MD, FACC 
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During the past 2 decades there has been a progressive 
revision of the role of digitalis in the management of con&s- 
tive heart failure. The availability of alternative drugs has 
reduced the dependence of the Gnician on digitalis as the 
principal approach to management of this disorder and has 
modified the approach todigitalis therapy in those patients in 
whom a valid indication for the drug continues to exist. 
What is the rationale for the we of digoxin in the 
management of patients with chronic congestive heart fait- 
we? We should acknowledge that digoxin is not necessarily 
the drug oftint choice after diuretics in o/l patients with this 
